CTOs on the Move

MDC Group

www.mdcomm.com

 
MDC Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mdcomm.com
  • 245 5th Ave
    New York, NY USA 10016
  • Phone: 212.679.3336

Executives

Name Title Contact Details

Similar Companies

NJMHI

NJMHI is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SetPoint Medical

SetPoint Medical is developing novel neuromodulation therapies to treat those who suffer from inflammatory diseases such as Crohn`s Disease and rheumatoid arthritis. The company is developing a proprietary and innovative neuromodulation therapy delivery platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy will provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payors less than 50% of what today`s leading biologic therapies cost.

Lumiata

Based in the heart of Silicon Valley, Lumiata is an Artificial Intelligence company purpose-built for the healthcare industry. Powered by over 100 million patient data records, clinical, risk, and financial algorithms, Lumiata employs some of the nation`s leading data science and machine learning talent. Lumiata enriches payers` and providers` analytic and predictive capabilities with a platform and pre-built models that help to manage healthcare costs and risk.

International Isotopes

International Isotopes is a Idaho Falls, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.